Steatohepatitis, Nonalcoholic
16
5
7
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
2 terminated out of 16 trials
66.7%
-19.8% vs benchmark
6%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (16)
Digital Therapy for Fatty Liver Disease
Using Hydroxychloroquine (HCQ) to Treat Steatohepatitis
Accuracy of Imaging Techniques in Diagnosing Steatohepatitis and Fibrosis in NAFLD Patients
The COherence of Scatter Identification and Exclusion Algorithm Study
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224
Ketogenic Diet in MASLD-related cACLD
Prevalence of Steatosis and Steatohepatitis in Patients Undergoing Bariatric Surgery; a Biopsy-based Study
Formula Diet Treatment for NASH Patients.
Safety of DNP007 in Healthy Subjects
Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
Integrated Approaches for Identifying Molecular Targets in Liver Disease
Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients
Effect of Probiotics in Non-alcoholic Fatty Liver Disease and Steatohepatitis
The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis
Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt